INDIANAPOLIS, May 27, 2015 /PRNewswire/ -- New clinical data demonstrating the range of treatment options represented in Lilly's (NYSE : LLY ) diabetes portfolio will be presented in 79 abstracts on June 5-9, at the 75th American Diabetes Association (ADA)® Scientific Sessions in Boston. These presentations reflect Lilly's efforts to enhance scientific knowledge and improve current approaches to diabetes management. Thirty-five of the abstracts will be presented as part of the Boehringer Ingelheim-Lilly Diabetes alliance.
"The Scientific Sessions are an important opportunity for researchers and healthcare and industry professionals to come together and share learnings and advances in diabetes care," said David Kendall, M.D., vice president of Medical Affairs, Lilly Diabetes. "We look forward to communicating significant new data that showcase the full range of our diabetes portfolio."
Among the data being presented at this year's Scientific Sessions are:
Basal Insulin Peglispro
Lilly will share new efficacy and safety data for its investigational basal insulin peglispro (BIL), including two late-breaking abstracts and the first data presentations from the seven Phase III IMAGINE trials in patients with type 1 and type 2 diabetes. A total of 19 abstracts will be presented, including three oral presentations:
- Saturday, June 6, 1:45 to 3:45 p.m., "Basal Insulin Analogs: New Evidence" Oral Session
- 1:45 p.m.: Basal Insulin Peglispro (BIL) is Superior to Insulin Glargine (GL) in Reducing HbA1c at 52 Weeks in Insulin-Naïve T2D Patients (Pts) Treated with Oral Antihyperglycemic Medications (OAMs): IMAGINE 2 (Lead author: M.J. Davies) [Presentation No. 93-OR]
- 2 p.m.: Reduced Intra-subject Variability of Basal Insulin Peglispro (BIL) Compared to Insulin Glargine in Patients with Type 1 Diabetes Mellitus (T1DM) (Lead author: T. Heise) [Presentation No. 94-OR]
- 2:15 p.m.: Greater HbA1c Reduction with Basal Insulin Peglispro (BIL) v Insulin Glargine (GL) in an Open-label, Randomized Study in T1D Patients (pts): IMAGINE 1 (Lead author: S. K. Garg) [Presentation No. 95-OR]
Additional data showing BIL's effect on hypoglycemia, liver enzymes and lipids will also be presented.
Lilly will present nine abstracts for Trulicity, a once-weekly, glucagon-like peptide-1 receptor agonist (GLP-1 RA) injectable prescription medication to improve blood sugar in adults with type 2 diabetes along with diet and exercise. Among these presentations are new data comparing the safety and efficacy of Trulicity to other common diabetes medicines in multinational patient populations, and a meta-analysis showing no increased risk of cardiovascular events in patients taking Trulicity. Select presentations are as follows:
- Saturday, June 6, 11:30 a.m. to 1:30 p.m., General Poster Session
- Efficacy and Safety of Once-weekly Dulaglutide versus Once-daily Liraglutide in Japanese Patients with Type 2 Diabetes (Lead author: T. Takamura) [Poster No. 1111-P]
- Once Weekly Dulaglutide Does Not Increase the Risk for CV Events in Type 2 Diabetes: A Pre-Specified CV Meta-Analysis of Prospectively Adjudicated CV Events (Lead author: K.C. Ferdinand) [Poster No. 1127-P]
- Monday, June 8, 8 a.m. to 10 a.m., "Update on GLP-1 Receptor Agonists" Oral Session
- Efficacy and Safety of Once-Weekly Dulaglutide vs. Insulin Glargine in Combination with Metformin and/or a Sulfonylurea in Predominantly Asian Patients with Type 2 Diabetes (Lead author: W. Wang) [Presentation No. 280-OR]
For more information on presentations, please click here.
Trulicity is a once-weekly, glucagon-like peptide-1 receptor agonist (GLP-1 RA) injectable prescription medicine indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Trulicity is not insulin. It acts like GLP-1, a natural hormone, helping the body release its own insulin when patients eat to control blood sugar.
Trulicity comes in a pen and does not require the patient to mix, measure, or handle the needle. It can be taken any time of day, with or without meals, and should be injected subcutaneously in the abdomen, thigh, or upper arm.
Indication and Limitations of Use for Trulicity
Trulicity is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Trulicity is not recommended as first-line therapy for patients inadequately controlled on diet and exercise because of uncertain relevance in rodent C-cell tumor findings to humans. Prescribe only if potential benefits outweigh potential risks. It has not been studied in patients with a history of pancreatitis, and other antidiabetic therapies should be considered. Trulicity is not for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. Trulicity is not a substitute for insulin and has not been studied in combination with basal insulin. Trulicity has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and is not for patients with pre-existing severe gastrointestinal disease.
Important Safety Information for Trulicity™
WARNING: RISK OF THYROID C-CELL TUMORS
Trulicity is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with a prior serious hypersensitivity reaction to dulaglutide or any of the product components.
Risk of Thyroid C-cell Tumors: Cases of MTC in patients treated with liraglutide, another GLP-1 receptor agonist (GLP-1 RA), have been reported in the postmarketing period; the data in these reports are insufficient to establish or exclude a causal relationship between MTC and GLP-1 RA use in humans. If serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging, the patient should be further evaluated.
Pancreatitis: Has been reported in clinical trials. Observe patients for signs and symptoms including persistent severe abdominal pain. If pancreatitis is suspected, discontinue Trulicity promptly. Do not restart if pancreatitis is confirmed. Consider other antidiabetic therapies in patients with a history of pancreatitis.
Hypoglycemia: The risk of hypoglycemia is increased when Trulicity is used in combination with insulin secretagogues (e.g., sulfonylureas) or insulin. Patients may require a lower dose of the sulfonylurea or insulin to reduce the risk of hypoglycemia.
Hypersensitivity Reactions: Systemic reactions were observed in patients receiving Trulicity in clinical trials. Instruct patients who experience symptoms to discontinue Trulicity and promptly seek medical advice.
Renal Impairment: In patients treated with GLP-1 RAs, there have been postmarketing reports of acute renal failure and worsening of chronic renal failure, sometimes requiring hemodialysis. A majority of reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration. In patients with renal impairment, use caution when initiating or escalating doses of Trulicity and monitor renal function in patients experiencing severe adverse gastrointestinal reactions.
Severe Gastrointestinal Disease: Use of Trulicity may be associated with gastrointestinal adverse reactions, sometimes severe. Trulicity has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and is therefore not recommended in these patients.
Macrovascular Outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with Trulicity or any other antidiabetic drug.
The most common adverse reactions reported in ≥5% of Trulicity-treated patients in placebo-controlled trials (placebo, Trulicity 0.75 mg, and Trulicity 1.5 mg) were nausea (5.3%, 12.4%, 21.1%), diarrhea (6.7%, 8.9%, 12.6%), vomiting (2.3%, 6.0%, 12.7%), abdominal pain (4.9%, 6.5%, 9.4%), decreased appetite (1.6%, 4.9%, 8.6%), dyspepsia (2.3%, 4.1%, 5.8%), and fatigue (2.6%, 4.2%, 5.6%).
Gastric emptying is slowed by Trulicity, which may impact absorption of concomitantly administered oral medications. Use caution when oral medications are used with Trulicity. Drug levels of oral medications with a narrow therapeutic index should be adequately monitored when concomitantly administered with Trulicity. In clinical pharmacology studies, Trulicity did not affect the absorption of the tested, orally administered medications to a clinically relevant degree.
Pregnancy: There are no adequate and well-controlled studies of Trulicity in pregnant women. Use only if potential benefit outweighs potential risk to fetus.
Nursing Mothers: It is not known whether Trulicity is excreted in human milk. A decision should be made whether to discontinue nursing or to discontinue Trulicity, taking into account the importance of the drug to the mother.
Pediatric Use: Safety and effectiveness of Trulicity have not been established and use is not recommended in patients less than 18 years of age.
Please see Instructions for Use included with the pen.
DG HCP ISI 20APR2015
Approximately 29 million Americans and an estimated 387 million people worldwide have type 1 and type 2 diabetes. Type 2 diabetes is the most common type, accounting for an estimated 90 to 95 percent of all diabetes cases. Diabetes is a chronic disease that occurs when the body either does not properly produce, or use, the hormone insulin.
About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we work to meet the diverse needs of people with diabetes through research and collaboration, a broad and growing product portfolio and a continued commitment to providing real solutions—from medicines to support programs and more—to make lives better. For more information, visit www.lillydiabetes.com.
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and newsroom.lilly.com/social-channels.
This press release contains forward-looking statements about an investigational compound basal insulin peglispro, which is currently in development for the treatment of diabetes and Trulicity for the treatment of type 2 diabetes along with diet and exercise. It reflects Lilly's current beliefs; however, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development and commercialization. There is no guarantee that future study results and patient experience will be consistent with study findings to date or that basal insulin peglispro will receive required regulatory approvals or that Trulicity will prove to be commercially successful. For further discussion of these and other risks and uncertainties, please see Lilly's latest Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.
 Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA: U.S. Department of Health and Human Services; 2014.
 International Diabetes Federation. IDF Diabetes Atlas, 6th edn. Brussels, Belgium: International Diabetes Federation, 2014. http://www.idf.org/diabetesatlas.
Refer to: Candace Johnson, firstname.lastname@example.org, (317) 755-9143
SOURCE Eli Lilly and Company